Hansa Biopharma AB HNSBF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $3.70
- Day Range
- $3.28–3.29
- 52-Week Range
- $2.90–4.58
- Bid/Ask
- $2.56 / $2.90
- Shares Outstanding
- 99.73M
- Market Cap
- $328.02M
- Volume/Avg
- 5,970 / 14,304
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.43
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 131
Valuation
Metric | HNSBF |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 10.43 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | HNSBF |
|---|---|
Quick Ratio | 1.61 |
Current Ratio | 1.62 |
Interest Coverage | −2.94 |
Quick Ratio
HNSBF
Profitability
Metric | HNSBF |
|---|---|
Return on Assets (Normalized) | −63.48% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −100.80% |
Return on Assets
HNSBF
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|N!r!rf | LOCK|$&&p | $137B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|sVgJbXC | LOCK|dhPb | $99B | |||
| Moderna Inc MRNA | LOCK|<JD?#R | LOCK|&Cr | $90B | |||
| argenx SE ADR ARGX | LOCK|&HCBCV> | LOCK|lY | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|Dd#wr%& | LOCK|hj | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|??@$&Q?% | LOCK|!Z>?& | $31B | |||
| Incyte Corp INCY | LOCK|%hx&&K | LOCK|%f | $25B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|JZR?>b | LOCK|<c#^ | $22B | |||
| BioNTech SE ADR BNTX | LOCK|Q#?Vm^@ | LOCK|q> | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|cN<<W& | LOCK|%#L | $16B |
United States